NR2F6 and lung cancer: Specifically, CAR-T cells combined with NR2F6 gene modification might thus represent an opportunity to extend the clinical efficacy of CAR-T cell immunotherapy to the treatment of advanced/metastatic NSCLC lung cancer in the future.